Insights on the Musculoskeletal Disorders Drugs Global Market to 2030 – Identify Growth Segments for Investment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Musculoskeletal Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global musculoskeletal disorders drugs market as it emerges from the COVID-19 shut down.

The global musculoskeletal disorders drugs market is expected to grow from $81.08 billion in 2020 to $85.6 billion in 2021 at a compound annual growth rate (CAGR) of 5.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $100.76 billion in 2025 at a CAGR of 4%.

Companies Mentioned

• F. Hoffmann-La Roche Ltd
• GlaxosmithKline Plc
• Pfizer Inc
• Abbott Laboratories Inc
• Daiichi Sankyo Company

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders.

Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union’s General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a report by Ernst and Young in 2018, Fortune 500 companies are spending $7.8 billion to comply with GDPR regulations. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market.

The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the Population Reference Bureau, the share of population over the age of 65 in the global population increased from 8% in 2015 to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Musculoskeletal Disorders Drugs Market Characteristics

4. Musculoskeletal Disorders Drugs Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Musculoskeletal Disorders Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Musculoskeletal Disorders Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Musculoskeletal Disorders Drugs Market Trends and Strategies

8. Impact of COVID-19 on Musculoskeletal Disorders Drugs

9. Musculoskeletal Disorders Drugs Market Size and Growth

10. Musculoskeletal Disorders Drugs Market Regional Analysis

10.1. Global Musculoskeletal Disorders Drugs Market, 2020, by Region, Value ($ Billion)

10.2. Global Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region

10.3. Global Musculoskeletal Disorders Drugs Market, Growth and Market Share Comparison, by Region

11. Musculoskeletal Disorders Drugs Market Segmentation

11.1. Global Musculoskeletal Disorders Drugs Market, Segmentation by Type

11.2. Global Musculoskeletal Disorders Drugs Market, Segmentation by Distribution Channel

11.3. Global Musculoskeletal Disorders Drugs Market, Segmentation by Route of Administration

11.4. Global Musculoskeletal Disorders Drugs Market, Segmentation by Drug Classification

11.5. Global Musculoskeletal Disorders Drugs Market, Segmentation by Mode of Purchase

12. Musculoskeletal Disorders Drugs Market Metrics

12.1. Musculoskeletal Disorders Drugs Market Size, Percentage of GDP, 2015-2025, Global

12.2. Per Capita Average Musculoskeletal Disorders Drugs Market Expenditure, 2015-2025, Global

For more information about this report visit https://www.researchandmarkets.com/r/6mgxcu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900